01—Abstract
Summary
Summary of the 8-K filed March 17, 2025. Cited figures are marked; the original filing is the authoritative source.
Medtronic plc (MDT) announced a leadership transition within its finance department.
Jennifer M. Kirk, the Global Controller and Principal Accounting Officer, has resigned effective May 2, 2025, to pursue a CEO role at a private company, Exubrion Therapeutics. Investors should note that Ms. Kirk's departure is not attributed to any disagreements regarding Medtronic's operations or policies.
To ensure a seamless handover, Denise L. Blomquist, currently the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025.
Ms. Blomquist brings extensive experience to the role, having been with Medtronic for 21 years in various finance positions. Her compensation will align with industry standards, including participation in the company's incentive and long-term incentive plans.
02—Key points
Key Highlights
- Principal Accounting Officer Jennifer M. Kirk to resign effective May 2, 2025.
- Ms. Kirk's resignation is voluntary and not due to any disagreements with Medtronic.
- Denise L. Blomquist appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025.
- Ms. Blomquist has 21 years of experience within Medtronic's finance organization.
- Ms. Blomquist's compensation will be commensurate with her role and include participation in Medtronic's incentive plans.
- No family relationships or reportable transactions exist between Ms. Blomquist and Medtronic's directors or executive officers.
03—Questions
Frequently Asked Questions
What is the reason for Jennifer M. Kirk's departure?
Jennifer M. Kirk is resigning to become the chief executive officer of Exubrion Therapeutics, a privately held company. Her resignation is stated to be voluntary and not a result of any disagreements regarding Medtronic's operations, policies, or practices.
Who is replacing Jennifer M. Kirk as Principal Accounting Officer?
Denise L. Blomquist, who currently serves as the Assistant Global Controller, has been appointed as the new Global Controller and Principal Accounting Officer, effective March 17, 2025.
What is Denise L. Blomquist's experience at Medtronic?
Ms. Blomquist has been employed at Medtronic since 2004, accumulating 21 years of experience within the finance organization in roles of increasing responsibility.
Will Ms. Kirk remain with Medtronic during the transition period?
Yes, Ms. Kirk will remain with Medtronic through May 2, 2025, to support a smooth transition to Ms. Blomquist.
04—Continue